Price
CHART BY
Frequently asked questions
What is the Earnings Per Share (EPS) for Chrome Holding Co. Class A?
Chrome Holding Co. Class A's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -8.816. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Chrome Holding Co. Class A's stock?
Currently, 2 analysts cover Chrome Holding Co. Class A's stock, with a consensus target price of $8.40. Analyst ratings provide insights into the stock's expected performance.
What is Chrome Holding Co. Class A's revenue over the trailing twelve months?
Over the trailing twelve months, Chrome Holding Co. Class A reported a revenue of $174.90M.
What is the EBITDA for Chrome Holding Co. Class A?
Chrome Holding Co. Class A's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$181.65M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Chrome Holding Co. Class A?
Chrome Holding Co. Class A has a free cash flow of -$155.85M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Chrome Holding Co. Class A have, and what sector and industry does it belong to?
Chrome Holding Co. Class A employs approximately 265 people. It operates in the Health Care sector, specifically within the Biotechnology industry.
Financials
- EPS (TTM)
- -8.816
- Revenue (TTM)
- $174.90M
- EBITDA (TTM)
- -$181.65M
- Free Cashflow (TTM)
- -$155.85M
Analyst Ratings
The price target is $8.40 and the stock is covered by 2 analysts.
Buy
1
Hold
0
Sell
1
Information
Chrome Holding Co. is a consumer genetics and research company, which engages in assisting people to access, understand, and benefit from the human genome. It operates through the Consumer and Research Services, and Therapeutics segments. The Consumer and Research Services segment consists of Personal Genome Service, Telehealth Business, and Research Services. The Therapeutics segment focuses on the genetic insights of genetic and phenotypic information. The company was founded by Anne E. Wojcicki in 2006 and is headquartered in San Francisco, CA.
- Employees
- 265
- Industries
- Biotechnology
- Sector
- Health Care
Identifier
- Primary Ticker
- ME
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet